NDAORALCAPSULE, EXTENDED RELEASE
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
ISORDIL (isosorbide dinitrate) by Thayer Medical is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL (isosorbide dinitrate) is an oral extended-release nitrate vasodilator used for the treatment and prevention of angina pectoris. It works by relaxing vascular smooth muscle, promoting peripheral vasodilation, reducing cardiac preload and afterload, and dilating coronary arteries. The drug is indicated for patients requiring chronic anti-anginal therapy.
$0.068MPart D
Pre-LaunchPre-launch product with minimal current market presence suggests nascent commercial infrastructure and early-stage team building opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on ISORDIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.